The American Journal of Managed Care3d
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
pharmaphorum10d
Biogen, Eisai double down on Alzheimer's with lecanemab filing
Like Aduhelm (aducanumab) lecanemab – also known as BAN2401 – is another amyloid-directed antibody but has a slightly different mechanism, targeting soluble amyloid beta protofibrils which ...
New Treatments for Alzheimer’s Disease
The drugs, aducanumab (Aduhelm) and lecanemab (Leqembi), were approved in June 2021 and January 2023, respectively. Both ...
ebm.bmj11mon
28 A perfect storm: expanded disease definitions in alzheimer’s disease and the new era of disease-modifying drugs in mild cognitive impairment
The first disease-modifying drug in AD, Aducanumab, was approved by the FDA in June 2021, followed by Lecanemab in January 2023. These approvals were based on reduction of amyloid β plaques with an ...